Positive Topline Results for Efgartigimod in Ocular MG

by admin | Mar 2, 2026 | Health

Spread the love

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.
Medscape Medical News

← Inside the U.S.–Indonesia Reciprocal Trade Agreement: A Quiet Reordering of Economic Relations Can Fecal Transplants Enhance Immunotherapy? New Evidence →

Written By

Written by Albert Pham, News Curator and Blogger

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Sep 25, 2026 | albertpham, Economy_finances, Health, Politics

Harvard and MIT professors are moving to Canadian universities as Canada invests billions to attract global researchers amid U.S. research funding uncertainty.

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

Sep 22, 2026 | albertpham, Economy_finances, Health

U.S. customs changes could restrict Americans’ access to cheaper prescription drugs from Canada and other foreign pharmacies starting in October.

Positive Topline Results for Efgartigimod in Ocular MG

Written By

Related Posts

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated